Cao Shang-Mei, Chen Bo-Lin, Zou Zhen-Zhen, Yang Shao-Zhe, Fu Xiu-Hong
Luohe Central Hospital, The First Affiliated Hospital of Luohe Medical College, Henan Key Laboratory of Fertility Protection and Aristogenesis, Shaoling District, Luohe, China.
Front Pharmacol. 2024 Dec 20;15:1418111. doi: 10.3389/fphar.2024.1418111. eCollection 2024.
An abundance of experimental evidence indicates that icariin (ICA) could potentially exert an anti-tumor effect on ovarian cancer (OC). Nevertheless, the reliability of this evidence remains ambiguous. This study aimed to explore the impact of ICA on OC and the underlying mechanisms.
Bioinformatics analysis was employed to pinpoint ICA-targeted genes and signaling pathways implicated in OC, utilizing network pharmacology. Subsequently, PubMed, EMBASE, and Web of Science databases were systematically searched from 2001 through June 2023 for trials evaluating the anti-tumor efficacy of conventional ICA versus placebo in OC. The pathways and genes identified in the literature were recorded, and the therapeutic targets were statistically analyzed and compared with the predicted targets from network pharmacology to confirm the precision of the targets.
Fourteen target genes were validated with success. The pathways corresponding to the remaining genes-excluding these 14-were analyzed and found to be primarily associated with cell apoptosis, anti-tumor, and other related pathways. Out of the 76 studies retrieved, eight fulfilled the inclusion criteria. The subsequent meta-analysis suggested that ICA treatment was significantly correlated with reduced cell growth and induced apoptosis. This study demonstrated a certain efficacy of ICA compared to placebo in enhancing anti-tumor outcomes, characterized by increased abilities in reducing cell growth and inducing apoptosis. The pathways involved in the therapeutic effect may be linked to cell apoptosis and anti-tumor mechanisms.
大量实验证据表明，淫羊藿苷（ICA）可能对卵巢癌（OC）发挥抗肿瘤作用。然而，这一证据的可靠性仍不明确。本研究旨在探讨ICA对OC的影响及其潜在机制。
采用生物信息学分析，利用网络药理学确定与OC相关的ICA靶向基因和信号通路。随后，系统检索了PubMed、EMBASE和Web of Science数据库，从2001年至2023年6月，查找评估传统ICA与安慰剂在OC中抗肿瘤疗效的试验。记录文献中确定的通路和基因，并对治疗靶点进行统计分析，与网络药理学预测的靶点进行比较，以确认靶点的准确性。
成功验证了14个靶基因。对除这14个基因外其余基因对应的通路进行分析，发现主要与细胞凋亡、抗肿瘤及其他相关通路有关。在检索到的76项研究中，8项符合纳入标准。随后的荟萃分析表明，ICA治疗与细胞生长减少和诱导凋亡显著相关。本研究表明，与安慰剂相比，ICA在增强抗肿瘤效果方面具有一定疗效，其特征是降低细胞生长和诱导凋亡的能力增强。治疗效果所涉及的通路可能与细胞凋亡和抗肿瘤机制有关。
